COR
Cencora, Inc. NYSE$304.00
Mkt Cap $59.3B
52w Low $271.00
31.0% of range
52w High $377.54
50d MA $335.15
200d MA $328.14
P/E (TTM)
37.9x
EV/EBITDA
17.9x
P/B
33.7x
Debt/Equity
7.1x
ROE
85.2%
P/FCF
18.9x
RSI (14)
—
ATR (14)
—
Beta
0.72
50d MA
$335.15
200d MA
$328.14
Avg Volume
1.4M
About
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order p…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 4, 2026 | AMC | 4.05 | 4.08 | +0.7% | 329.97 | +1.9% | +6.7% | +8.9% | +10.1% | +9.1% | +10.8% | +8.6% | — |
| Nov 5, 2025 | AMC | 3.79 | 3.84 | +1.3% | 354.00 | -0.5% | +1.8% | +1.9% | +3.0% | +3.1% | +2.7% | -4.1% | — |
| Aug 6, 2025 | AMC | 3.85 | 4.00 | +3.9% | 283.78 | -0.9% | -1.9% | +0.5% | +2.4% | +1.9% | +2.6% | +3.1% | — |
| May 7, 2025 | AMC | 4.11 | 4.42 | +7.5% | 304.58 | -1.2% | -6.8% | -7.1% | -8.6% | -8.4% | -8.3% | -5.1% | — |
| Feb 5, 2025 | AMC | 3.50 | 3.73 | +6.6% | 253.28 | -1.1% | -2.8% | -2.1% | -2.7% | -2.6% | -3.8% | +0.5% | — |
| Nov 6, 2024 | AMC | 3.23 | 3.34 | +3.4% | 245.38 | +1.5% | +1.0% | +1.2% | +1.5% | +1.4% | +1.9% | -0.8% | — |
| Jul 31, 2024 | AMC | 3.22 | 3.34 | +3.7% | 237.88 | +0.9% | +2.8% | +4.1% | +1.4% | +0.8% | +1.4% | +0.7% | — |
| May 1, 2024 | AMC | 3.69 | 3.80 | +3.0% | 229.20 | -0.3% | -1.9% | -2.3% | -2.3% | -1.1% | -2.2% | -1.1% | — |
| Jan 31, 2024 | AMC | 2.89 | 3.28 | +13.5% | 232.68 | -0.0% | +1.8% | +1.0% | +0.7% | +1.0% | +2.1% | +1.9% | — |
| Nov 2, 2023 | AMC | 2.81 | 2.86 | +1.8% | 192.18 | +1.4% | +1.6% | +2.4% | +2.0% | +2.4% | +2.4% | +6.0% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 28 | William Blair | Initiates | Mkt Perform | — | $310.16 | $310.50 | +0.1% | +0.6% | +0.4% | -0.7% | -2.0% | — |
| Apr 8 | Evercore ISI | Maintains | Outperform → Outperform | — | $320.89 | $323.45 | +0.8% | +1.3% | +0.5% | -0.0% | -0.6% | -0.3% |
| Feb 13 | Barclays | Maintains | Overweight → Overweight | — | $351.06 | $352.66 | +0.5% | +2.8% | +2.5% | +2.6% | +2.3% | +2.9% |
| Feb 10 | JP Morgan | Maintains | Overweight → Overweight | — | $363.27 | $362.47 | -0.2% | -0.9% | +0.7% | -3.4% | -0.7% | -0.9% |
| Feb 10 | Wells Fargo | Maintains | Overweight → Overweight | — | $363.27 | $362.47 | -0.2% | -0.9% | +0.7% | -3.4% | -0.7% | -0.9% |
| Feb 5 | Evercore ISI | Maintains | Outperform → Outperform | — | $329.97 | $336.08 | +1.9% | +6.7% | +8.9% | +10.1% | +9.1% | +10.8% |
| Jan 29 | Morgan Stanley | Upgrade | Equal Weight → Overweight | — | $350.54 | $354.78 | +1.2% | +0.4% | +2.5% | +3.7% | +3.2% | -5.9% |
| Jan 22 | Jefferies | Upgrade | Hold → Buy | — | $351.75 | $356.14 | +1.2% | +0.2% | +0.5% | +1.1% | +1.2% | -0.3% |
| Jan 5 | BofA Securities | Maintains | Neutral → Neutral | — | $338.87 | $337.31 | -0.5% | +0.6% | +2.2% | +0.5% | -0.9% | -0.9% |
| Nov 11 | Wells Fargo | Maintains | Overweight → Overweight | — | $364.65 | $363.64 | -0.3% | +0.1% | -0.3% | +0.2% | -0.7% | +0.1% |
Recent Filings
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
COR's disclosure of forward-looking statements about EyeSouth Partners suggests potential strategic developments or operational updates that investors should monitor closely for impact on growth projections and earnings expectations.
Mar 23
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
The 8-K contains only standard forward-looking statement disclaimers without material news, suggesting COR has no significant developments to disclose at this time.
Mar 17
8-K
Cencora, Inc. -- 8-K Filing
Cencora shareholders voted to approve executive compensation for fiscal 2025 and ratified Ernst & Young as the independent auditor for fiscal 2026.
Mar 6
8-K · 8.01
!! High
Cencora, Inc. -- 8-K 8.01: Material Event / Announcement
Cencora agreed to acquire MWI Veterinary Supply through a merger with Covetrus, valuing MWI at $3.5 billion enterprise value.
Feb 18
8-K · 1.01
! Medium
Cencora, Inc. -- 8-K 1.01: Financing / Debt Agreement
Cencora issued 2029 convertible notes under an existing indenture framework with U.S. Bank Trust Company, expanding its debt financing options and extending maturity obligations into 2029.
Feb 13
8-K · 7.01
! Medium
Cencora, Inc. -- 8-K 7.01: Regulation FD Disclosure
Cencora disclosed material information via news release, which investors should review in the attached exhibit for updates on company developments or financial results.
Feb 11
8-K
Cencora, Inc. -- 8-K Filing
Cencora's 8-K filing reveals material corporate developments that could impact near-term stock performance, requiring investors to immediately review the specific disclosures to assess whether the news is positive or negative.
Feb 10
8-K · 7.01
! Medium
Cencora, Inc. -- 8-K 7.01: Regulation FD Disclosure
Cencora disclosed non-material information to the SEC under Regulation FD, clarifying this disclosure isn't incorporated into other filings and carries limited liability implications for investors.
Feb 4
Data updated apr 25, 2026 2:41am
· Source: massive.com